Free public records show Hospira Inc in 26 of the markets we cover. It is not a key player in our research.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
180 approvals with a product on the US market
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.
10 510(k) clearances and PMA approvals since 2015
Source: FDA 510(k) and PMA databases, 510(k) clearances, and PMA approvals or changes, since 2015; newest shown. Retrieved 13 Nov 2026.
87 recalls since 2015 (45 for medicines, 42 for devices)
Source: openFDA, FDA enforcement reports (recalls) naming the firm, since 2015. Retrieved 13 Nov 2026.
Annual reports and other filings with the US Securities and Exchange Commission.
Source: SEC EDGAR, Company filings, CIK 1274057.
Markets we cover where free public records show Hospira Inc: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Hospira Inc is in.
Stories on the topics Hospira Inc works in.
170 WHO Member States report the use of traditional medicine. Adaptogens like ashwagandha, rhodiola and…
Read
Depression and anxiety cost the world about US$1 trillion a year. Ashwagandha has some evidence for stress…
Read
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read